Cure8 research brief
Why This Matters
This study identifies a fibroblast state tied to inflammation in both Crohn’s disease and ulcerative colitis and shows that restoring TCF21 in cells can reduce inflammatory signals, pointing to a new stromal-focused therapeutic concept.
Who Should Pay Attention
Researchers in IBD and stromal biology; translational scientists developing RNA/LNP therapies; clinicians interested in emerging therapeutic targets.
Study Snapshot
What To Know
This preprint reports a single-cell RNA-sequencing analysis identifying a conserved inflammation-associated fibroblast (IAF) population expanded in both Crohn’s disease and ulcerative colitis and a reduced TCF21/ADAMDEC1-expressing homeostatic fibroblast population in inflamed tissue.
The authors validated TCF21 depletion by multiplex immunofluorescence of human gastrointestinal tissues and used cytokine stimulation of human colonic fibroblasts to reproduce an IAF-like state in vitro.
They tested restoring TCF21 by delivering TCF21 mRNA in lipid nanoparticles to fibroblasts and observed partial suppression of inflammatory mediators (for example, reduced IL1B and IL6 expression) in these experimental systems.
Keep In Mind
Preprint on bioRxiv—results have not completed peer review. Findings are based on single-cell RNA-seq integration, tissue staining, and in vitro models; clinical relevance will need in vivo and clinical validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.